Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
|ClinicalTrials.gov Identifier: NCT01300871|
Recruitment Status : Terminated (Poor patient accrual)
First Posted : February 23, 2011
Last Update Posted : September 26, 2014
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer|
|Study Start Date :||January 2011|
|Study Completion Date :||January 2012|
Postmenopausal Women on Endocrine Therapy
Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
- Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).
- Comparison of Tamoxifen, AI or Tamoxifen plus AI [ Time Frame: 1 year ]Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.
- Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300871
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 3M9|
|Principal Investigator:||Lindsay Carlsson||University Health Network-Princess Margaret Hospital|